Thursday, 18 April 2024
Trending

[the_ad_group id="2845"]

Investing

Jefferies starts ‘Buy’ on BioLife Solutions stock, eyes set on cell therapy market By Investing.com

Jefferies starts 'Buy' on BioLife Solutions stock, eyes set on cell therapy market By Investing.com

[the_ad id="21475"]

[ad_1]

On Thursday, BioLife Solutions (NASDAQ:) stock, received a positive outlook from Jefferies, initiating coverage with a Buy rating and setting a price target of $22.00. The endorsement comes as the company prepares to divest its freezer business, a move expected to streamline its operations.

Jefferies highlighted that the divestiture of the freezer segment will allow BioLife Solutions to present a “cleaner story” as a pure-play entity in the cell and gene therapy space. This strategic shift is anticipated to lead to a more focused business model revolving around its cell processing tools and storage platform. With over 95% recurring revenue, the firm is poised for structurally higher double-digit growth, significant margin expansion opportunities, and improved cash flow.

The financial institution drew parallels between BioLife Solutions and other pure-play bioproduction companies, noting its specialized offerings to a diversified client base in both clinical and commercial biotech sectors. These factors contribute to a solid competitive moat due to sticky revenue streams.

The price target of $22.00 set by Jefferies is based on approximately 8.5 times the company’s estimated 2025 enterprise value to revenue, a premium compared to peers but aligned with industry standards. This valuation reflects a roughly 35% discount to Repligen (NASDAQ:) Corporation (NASDAQ:RGEN), yet remains consistent with the market positioning of other high-growth companies in the sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Here to Read the Full Original Article at All News…

[ad_2]

[the_ad id="21476"]